Jiangong Niu

Jiangong Niu

Auto-generated profile, based on publicly available information

Jiangong Niu

Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Journal of Clinical Oncology
Verified
Journal Article
Open access
CBCarlos H. Barcenas
Carlos H. Barcenas
JNJiangong Niu
Jiangong Niu
NZNing Zhang
Ning Zhang
YZYufeng Zhang
Yufeng Zhang
TBThomas Buchholz
Thomas Buchholz
SGSharon H. Giordano
Sharon H. Giordano
Purpose: To compare the risk of hospitalization between patients with early-stage breast cancer who received different chemotherapy regimens. Patient and Methods: We identified 3,567 patients older than age 65 years from the SEER/Texas Cancer Registry-Medicare database and 9,327 patients younger than age 65 years from the MarketScan database who were diagnosed with early-stage breast cancer between 2003 and 2007. The selection was nonrandomized and nonprospectively collected. We categorized patients according to the regimens they received: docetaxel (T) and cyclophosphamide (C), doxorubicin (A) and C, TAC, AC + T, dose-dense AC + paclitaxel (P) or AC + weekly P. We compared the rates of chemotherapy-related hospitalizations that occurred within 6 months of chemotherapy initiation and used multivariable logistic regression analysis to identify the factors associated with these hospitalizations. Results: Among patients younger than age 65 years, the hospitalization rates ranged from 6.2% (dose-dense AC + P) to 10.0% (TAC), and those who received TAC and AC + T had significantly higher rates of hospitalization than did patients who received TC. Among patients older than age 65 years, these rates ranged from 12.7% (TC) to 24.2% (TAC) and the rates of hospitalization of patients who received TAC, AC + T, AC, or AC + weekly P were higher than those of patients who received TC. Conclusion: TAC and AC + T were associated with the highest risk of hospitalization in patients younger than age 65 years. Among patients older than age 65 years, all regimens (aside from dose-dense AC + P) were associated with a higher risk of hospitalization than TC. Results may be affected by selection biases where less aggressive regimens are offered to frailer patients.

12 February 2021 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Open access
PDF file
ACAileen Chen
Aileen Chen
JNJiangong Niu
Jiangong Niu
ACAngel M. Cronin
Angel M. Cronin
YSYa-Chen Tina Shih
Ya-Chen Tina Shih
SGSharon Giordano
Sharon Giordano
DSDeborah Schrag
Deborah Schrag
Background: Understanding the sources of variation in the use of high-cost technologies is important for developing effective strategies to control costs of care. Palliative radiation therapy (RT) is a discretionary treatment and its use may vary based on patient and clinician factors. Methods: Using data from the SEER-Medicare linked database, we identified patients diagnosed with metastatic lung, prostate, breast, and colorectal cancers in 2010 through 2015 who received RT, and the radiation oncologists who treated them. The costs of radiation services for each patient over a 90-day episode were calculated, and radiation oncologists were assigned to cost quintiles. The use of advanced technologies (eg, intensity-modulated radiation, stereotactic RT) and the number of RT treatments (eg, any site, bone only) were identified. Multivariable random-effects models were constructed to estimate the proportion of variation in the use of advanced technologies and extended fractionation (>10 fractions) that could be explained by patient fixed effects versus physician random effects. Results: We identified 37,361 patients with metastatic lung cancer, 3,684 with metastatic breast cancer, 5,323 with metastatic prostate cancer, and 8,726 with metastatic colorectal cancer, with 34%, 27%, 22%, and 9% receiving RT within the first year, respectively. The use of advanced technologies and extended fractionation was associated with higher costs of care. Compared with the patient case-mix, physician variation accounted for a larger proportion of the variation in the use of advanced technologies for palliative RT and the use of extended fractionation. Conclusions: Differences in radiation oncologists’ practice and choices, rather than differences in patient case-mix, accounted for a greater proportion of the variation in the use of advanced technologies and high-cost radiation services.

11 January 2024 in Cancer Prevention Research
Verified
Journal Article
Closed access
PDF file
PRPaul J. Resong
Paul J. Resong
JNJiangong Niu
Jiangong Niu
GDGabrielle F. Duhon
Gabrielle F. Duhon
LFLewis E. Foxhall
Lewis E. Foxhall
SSSanjay Shete
Sanjay Shete
ITIakovos Toumazis
Iakovos Toumazis
Current lung cancer screening (LCS) guidelines rely on age and smoking history. Despite its benefit, only 5%–15% of eligible patients receive LCS. Personalized screening strategies select individuals based on their lung cancer risk and may increase LCS's effectiveness. We assess current LCS practices and the acceptability of personalized LCS among primary care providers (PCP) in Texas. We surveyed 32,983 Texas-based PCPs on an existing network (Protocol 2019-1257; PI: Dr. Shete) and 300 attendees of the 2022 Texas Academy of Family Physicians (TAFP) conference. We analyzed the responses by subgroups of interest. Using nonparametric bootstrap, we derived an enriched dataset to develop logistic regression models to understand current LCS practices and acceptability of personalized LCS. Response rates were 0.3% (n = 91) and 15% (n = 60) for the 2019–1257 and TAFP surveys, respectively. Most (84%) respondents regularly assess LCS in their practice. Half of the respondents were interested in adopting personalized LCS. The majority (66%) of respondents expressed concerns regarding time availability with the personalized LCS. Most respondents would use biomarkers as an adjunct to assess eligibility (58%), or to help guide indeterminate clinical findings (63%). There is a need to enhance the engagement of Texas-based PCPs in LCS. Most of the respondents expressed interest in personalized LCS. Time availability was the main concern related to personalized LCS. Findings from this project highlight the need for better education of Texas-based PCPs on the benefits of LCS, and the development of efficient decision tools to ensure successful implementation of personalized LCS. Prevention Relevance: Personalized LCS facilitated by a risk model and/or a biomarker test is proposed as an alternative to existing programs. Acceptability of personalized approach among PCPs is unknown. The goal of this study is to assess the acceptability of personalized LCS among PCPs.

1 July 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
DGDesmond C. Garner
Desmond C. Garner
JNJiangong Niu
Jiangong Niu
CSCarly F. Stender
Carly F. Stender
CHCandice L. Hinkston
Candice L. Hinkston
SGSharon H. Giordano
Sharon H. Giordano
MWMackenzie R. Wehner
Mackenzie R. Wehner

2 February 2024
Verified
Other
Open access
PRPaul J. Resong
Paul J. Resong
JNJiangong Niu
Jiangong Niu
GDGabrielle F. Duhon
Gabrielle F. Duhon
LFLewis E. Foxhall
Lewis E. Foxhall
SSSanjay Shete
Sanjay Shete
ITIakovos Toumazis
Iakovos Toumazis
Supplemental Table 1. Respondent demographics

2 February 2024
Verified
Other
Open access
PRPaul J. Resong
Paul J. Resong
JNJiangong Niu
Jiangong Niu
GDGabrielle F. Duhon
Gabrielle F. Duhon
LFLewis E. Foxhall
Lewis E. Foxhall
SSSanjay Shete
Sanjay Shete
ITIakovos Toumazis
Iakovos Toumazis
Supplemental Table 1. Respondent demographics